Tuesday, June 10, 2014

Medicinal Plants In Health Management

The struggle of a man against disease and death is as old as the history itself. On the basis of skill, knowledge and practices based on the theories, beliefs & experiences indigenous all civilizations has developed their own treatment system which is now called as traditional treatment system. The base of almost all such treatment system is plants. Various as scholar and medical men, since the vedic period dawn to the present century, have contributed a lot on the use of medicinal plants in health care.

Plants are the most ancient source of drugs and the plant based medicaments, the countrymen’s prime therapeutic weapon, are still is front line today for treating a large number of diseases. According to Professor N.R. Fransworth the plants are “The sleeping giants of drug development today and will represent in future as first class source for new medicaments.

The most established traditional system is Ayurveda. The objectives of Ayurveda are Dhatu Samya, Swastha Vritta and Atura Vritta. Proper cure of a disease entirely depends upon rational interaction of four limbs of therapies or chikitsa chatushpada and drug is one of the components of therapy. The material Media of Ayurveda is very vast. It comprises of Plants, animals and metals and aquatic products but plant drugs occupy a large area for the prevention and promotion of health and treatment of Disease.
It may be noted that Ayurveda (sanskrit Ayur : life, Veda : science, Knowledge) is the ancient Indian system of health management which is still widely practiced in the sense of “holistic’ approach, especially for metabolic disorders. Ayurvedic medicines are mostly based on plant materials. The entire mountainous region of the country is considered a vast repository of medicinal herbs. It has been estimated that the sources of 80% Ayurvedic medicines are found in the western Himalayas.

A medicinal plant is any plant which is one or more of its organs substances that can be used for therapeutic purposes or which are precursors for chemo pharmaceutical semi-synthesis. The definition makes it possible to distinguish between the medicinal plants that are already known whose therapeutic character or a precursor of certain molecular have been established scientifically and the other plants which are regarded as medicinal but have not yet been subjected to thorough scientific study. Researches for the identification, development and utilization of plants should be given high priority for the development of Indigenous system of health care in order to reduce drug bills and develop more acceptable and more readily acceptable to the people and with better coverage.

The following are the some of the examples of plants which are used in primary health care extensively specially in the Rural Area:
1
Tulsi
Ocimum sanctum
Promotes immunity
2
Bhallatak
Semicarpus anacardium
Anti-cancer agent
3
Ashwagandha
Wiothania somnifera
General nervine tonic
4
Amalaki
Emblica officinals
Rejuvenate (resayana)
5
Manookharni
(Brahmi)
Hydsrocotyl ariatica
Improves memory and intelligence
6
Shankhapushpi
Convulvulus pluricalis
Improves memory and intelligence
7
Vacha
Acorus colamus
Improves speech in children
8
Jyolishmati
Collesterus pariniculala
Improves mental health
9
Arguna
Terminalia Arjuna
Most effective cardio tonic
10
Shirish
Albebia lebeck
Anti-asthma
11
Haridra
Curcuma longum
Anti-Allergic
12
Katuki
Picrorrhiza Kurroa
Jaundiced Hepatitis
13
Punarnawa
Boerhavia diffusa
Kidney disorders
14
Varuna
Gitavia deligiosa
Bladder disorders
15
Kapikachu
Mucona Pruriens
Impotency
16
Shatavari
Asparagus racimosus
Galactogogue
17
Bala
Sida cardifolia
Baby tonic
18
Japakusum
Haviscus Rosa cyanosus
Antifertility agent
19
Vijaysar
Ptericorpus Marsupium
Ant diabetic
20
Kutaj
Holerene Antidysenterica
Colitis

Some of the drugs which have come to light in our experience to have significant action and the observation have been also supported. Scientific observations are as follows

Psychotropic drugs : A group of drugs which have been observed as medhya drugs and few others have shown to have definite action on brain called as psychotropic drugs e.g.
  • Shankhapushupi      -           Convolvulus Pluricaulis choisy
  • Mandukharmi           -           Centella Asiatica
  • Brahmi                      -           Bacopa – monnieri
  • Ashwagandha          -           Withania somnifera Dunal
  • Vacha                        -           Acorus calamus
  • Jyotismati                  -           Calastrus paniculatus
  • Jatamansi                  -           Nordostachys Jatamansi
The drugs have a true tranquilizing effect on brain without inducing any hangover or dullness of brain. These are helpful in inducing sleep and freshness of brain for better performance, thus improving the intellectual activity and memory also. These plants also help as to come out of severe complexes, depression and antisocial trends e.g. suicide, hemisuidal, homicidal etc.
By their virtue of having effect on psychic they are also effective for the management several psychosomatic disorders. Heart disease, hypertensions peptic ulcer, ulcerative colitis are some of the notable disease of this group. These drugs have also anabolic effect on general metabolism. Cardio vascular drugs: cardio vascular disease is a great cause of mortality like cancer in the western countries. But the developing countries are no more exception. The incidence of high B.P., heart disease, and obesity is in increasing in China and India. Usually the people have a feeling that it is disease of affluent society and the treatment as only possible by the modern drugs. But none of them is true; there is description of this disease in Ayurvedic literature which is referred to be a contribution of 500 B.C. The treatment of heart disease is still in practice in Indian system of medicine. The effective drugs of cardiovascular system are as follows:
Arjun                          :Teminalia Arjuna
Gugulu                       : Balsamodendron mukul
Pushkarmula             : Inulr Recemosus
Shalpharmi                : Desmodium gangetiun
Karbir                         : Theretia Nereifolia
Kutha                          : Holerrbena – Antidysenterica
Rasona                       : Alliun – Sativum 
Thus a good number of cardio vascular drugs are in our urmamentorium of medicinal plants which can be developed as potent drugs in future.
Respiratory System:
According to Ayurveda respiratory system is the chief site of Kapha hence the disease also produce the symptoms of Kakha. Vata is also involved simultaneously in some disease as Bonchial Asthma. It is a well-known fact that if is a disease having ofstruction branch opathy. Obstruction may be because of the Oedoma/ inflammation of the mucosa or due to bronco – construction, forma is allergic inflammation due to excess of histamine like substances and the latter is because of the predominance of anticholenergic substance. Allergic manifestatias may produce several symptoms of respiratory tract disorder e.g. Allergic Rhinitis, Nasopharongitis Brynchitis etc. The following drugs have been found to be useful for amelioration of the above pathology.
Tulsi                   :Olimum sanctum
Sirisha               :Albizzia Leffeck benth
Kantkari             :Solan um xanthocarpum
Vasa                   :Adhatoda Vasca
Madhuyasti        :Curucuma Longa
Sunthi                 :Zingiber Feivale
Bibhitaka           :Terminalia Belerica
Tulsi is supposed to be most pious plant in Indian culture. No worship is complete without offering the tender leaves to God and then same is distributed among the masses for beneficial effect on health. The evidences are in favour that it is an immunostimulant thus providing increased general resistance for the prevention of disease. It is antipyretic, antinflamatery, expectorant and milid bronchodiloty thus of great help to the patient of upper respiratory and bronchial disease. Sirisha is known as an established drug for allergic disorders and branchal asthma. Charak has described it to be most effective vishghna (antitoxic drug). On Pharmacological study it is found to be antihistaminic and steroidogenc, plasma cortisol is increased within a week after the administration of the drug Active Principle is known to be a Saponin.
All above drugs may be used alone or in combination for the treatment of several types of respiratory system disease. Shirisadi compounds containing Shirisha, Kanthari, vasa and Madhyuasthi is popularly used as shiristi chey (tea). Sunthi.

Gastro – Intestinal: Statistics is evident that the incidence of gastro intestinal diseases in India is maximum. Broadly these can be classified in two groups (i) psychosomatic disease (ii) parasitic infection and a third group can be idiopathic. Among the first group peptic ulcer (parionon shula) irritable bowel syndrome and colitis are the common clinical entities available in our country. Ion the second group amoebiasis, giardiass and other worm infections are common e.g. round work, Hook worm, thread worm. There is a concept of Jatharagni in Ayurveda. Apart from that it also seems to help the absorption and metabolism. In case of hyperseoretion/Hyposecreation absorption becomes poor and the metabolism registers at a lowereble. So the malsecretion and malaobsoption syndrome are related to each other and produce several disease of G.I. tract which are often known as adiopathic e.g. Amlaphita, graham etc.

A good number of drugs have been worked out and found to be useful for the treatment of these disorders or follows :
Patola –    Gastritis
Nurikela – Pepticulcer
KLutaja –  Colis
Karanj –    Amoebiasis
Bilwa –      Amoebiasis
Palas –      Beeja – worm infections
Most of these drugs stimulate and digestive and help in regeneration of villi for a better absorption which leads to acceleration of metabolism. Some of the drugs are proved to be antihelimenthic and antiparasitic others offer symptomatic relief to the gastro intestinal symptoms.
Liver Dis-function:
The most common disease of liver is infective hepatitis (kamala) Though it is a fact that it is a self limiting disease and takes about 4 weeks to become alright but it has got a very deterimented effect on health, if the pathology continues come residual symptoms perrists it may turn into cirrhosis of liver which is fatel in due course of time.
Otherwise of the infection is fulminating it may take acute turn and patient may pass towards acute hepatic failure characterized by anasarca, hemorrhage, renal and curdic failure and the patient may succumb in no time.

Even in the normal course of the disease there can be four stages on the first week there is no jaundice, there is fever and loss of appetite and general weakness usually the cough and cold may be present with the beginning of the process. In the second week Jaundice is marked urine, stool, skin, nails, eyes everything becomes yellow, in the third week there may be inflammation of file canaliculi colangitis leading to intrapepaic obstruction and regurgitation of file in the blood producing a more deep Joundice and whiteclay colourd stool, in the fourth week the pathology may resolve  or pass to the stage of complication. Otherwise also, it the resolution is not complete the lesion may perrist as residual pepatitis. The following drugs hae been found to have a cholaratic effect and helping in the complete resolution of hepatitis, so these drugs have preventive as well as curative effect in patients of hepatitis.                                                                 
Kalmegh – Androgaphis panculata 
 Bhringraj – Eclipta alba
Amalaki – Emblica officinalis
Sarpankha – Tephrosia purpurea.

In clinical trial all these drugs in combination or as single drug can be used kalmegha and Amalaki combination are under clinical trial in our medicinal plants unit serum bilirubin comes down to normal range within to 2-3 weeks hepatitis is improved and there is no chance of having residual hepatitis in the end.

The discussion could be extended to any length but it is concluded with an optimistic note that India with its rich heritage of herbal medicine, its wealth of medicinal flora and necessary expertise in all relevant area would be able to offer leadership in the development of herbal medicine. It should, however be kept in mind that tomorrows citizens of India will have a better scientific temper and attitude and will not be satisfied to know merely that it works they will question how it works? Our development should be equipped to answer this questions.

Dhirendra V. Singh

Tuesday, February 25, 2014

4th Anniversary of Genelife Clinical Research



Not so long ago, on 26 Feb 2010 we started Genelife Clinical Research, after years of planning and analyzing the cost & expenses. On this day our dreams took-off with a lot of enthusiasm, promise and hope in the back drop of recession and limited resources. We knew that if we will survive that period we would have no limits. During those days we had to survive not only the recession but also against mighty established players. We survived that period and emerged as a winner in our own way. The first year was a very emotional year. We had gone through lots of pain and turbulence before we reached our 1st anniversary. But why I am talking about that now.. because this was an equally challenging year.

This year we will be remembering as the year of “reform and regret”. Across the country the quality of care of patients and clinical research was decreasing considerably. The necessary quality standards were available as standard in some places and were unavailable in others. Our regulation which was developed in a piecemeal fashion over a period of time was not able to manage the things properly and industry was in desperate need for reform- which finally happened this year. However, the planning, developing and implementation of this reform took almost a year, which almost killed the Clinical Research industry of India. Many competitor companies including some giants pull their curtains down; some changed their mode of operations. This changed the entire complexion of Clinical Research market, which to some extent is positive because now only those seriously involved companies are left in this serious business.

Everybody in healthcare industry was affected by this “silent” phase and we were no exception. However, with the confidence in our system and support of clients, friends and well-wishers we came out of this period. This could have been even better if we would have not lost some US FDA projects due to this regulatory complication. I still regret that decision of taking those projects in such an unstable regulatory environment. It was hard for us, but even larger concern and my deep apology to those sponsors whose time, energy and money wasted during this tenure.

Since inception, Genelife Clinical Research has focused on strong customer relationship with a vision "To be the most respected partner in providing product development and clinical research needs." The effort of giving the best is a kind of self-motivating mantra which probably separates us from the rest. And probably this is the only thing which helps us to emerge excellent from any given situation.

Looking back at the development of the entire year; it gives me a sense of achievement. We started the year on high note and anticipated a greater growth; however, with all the hiccups, what we achieved is remarkable growth not only in terms of project but also in terms of reach. We now have a global presence and soon we will be operating globally. We have implemented electronic CRF and looking forward to implement CTMS.

I would like to to attribute this year’s success to my team, which stuck to the basics & kept me away from taking any imprudent decisions. The secret of our success this year is not just doing the right thing but doing the right thing in customer centric way cost effectively. Very basic principle we understood our sponsor’s requirement and planned according to their requirement.
On this auspicious occasion, I sincerely appreciate the faith of clients on our ability. We are looking forward to deliver that trust in best possible way. I am greatful to all those who have directly or indirectly helped us to shape our dream and vision. But my greatest thanks to my colleagues and consultants for their commendable effort and believing the ideology of Genelife Clinical Research. This year belong to them and I feel proud to be a part of this excellent team.

I am looking forward for the same kind of trust, faith and support from everyone in future. I know if we perform this good, we will evolve even better in the coming year.

Thank You.

Kind Regards,
Dhirendra V. Singh

Friday, November 29, 2013

Genelife Clinical Research: Ophthalmology Clinical Trials



Genelife Clinical Research has started 12 Phase III Ophthalmology Clinical Trials for DCGI Submission. These 12 studies cover vide range of indications including dry eye, Ocular pain, Intra Ocular pressure, different types of conjunctivitis, pre & post cataract surgery etc. In these studies we are recruiting all kinds of patients from minor to old age people which will be a challenging task for us. 


We have already finished selecting sties for these studies. All the sites are selected very carefully as per the current DCGI guidelines including audio visual regulation. All these sites are multi-specialty/government hospitals with DCGI approved ethics committees and are distributed in all Geographical regions of India. During site selection we have considered seasonal variation as well as on recruitment prevalence of the particular ophthalmic condition from DSR, historic data and geographical location.
 
For adapting and absorbing the complexities aroused due the introduction of audio visual informed consent we have developed our electronic CRF which will be able to capture that also. This will help us to make a complete document for a patient for regulatory purpose and future regulatory audit purpose. During the site selection procedure we have made special emphasis on the infrastructure of site and computational knowledge of site personal.

Like our past studies we are hoping to complete these study before the time we proposed to our Sponsor. Hope we will achieve our target.
Kind Regards,

Rama Rajesh 
Project Manager 
Genelife Clinical Research

Tuesday, February 26, 2013

Genelife Clinical Research: III Anniversary


We perform at our intellectual best and by exceptional willingness when we know why and what we're doing; with this motivation Genelife Clinical Research was established (on 26th Feb 2010). Every one related to Genelife either employees, clients, consultants, investigators, vendors or well-wisher they all have played their role most effectively and efficiently in the establishment & development of Genelife Clinical Research. On the third anniversary of Genelife Clinical Research I would like to thank everybody who has worked to achieve our goal “To be the most respected partner in providing product development and clinical research needs.” We can say this, because we have been haired more than once by all our sponsors. 
The development of Genelife Clinical Research has proved that marketing and sales is not the only deciding factor for the development of an organization. Our continuous development is because of our young Operations & Biometrics team, which has shown the urge to reach their full potential in order to make each project successful. They proved that the strongest principle of growth lies in one’s choice. We were privileged to receive this choice from our esteemed clients who trusted in our capabilities and entrusted their important projects. Furthermore, our development is also credited to those clients who have given suggestions for process development in place of project, which was equally valuable. And with them we hope to strengthen our relation further. 

Genelife Clinical Research has seen several notable changes this year like: 
  • Web CRF 
  • New & bigger office 
  • Global presence; we now have major clients in Australia, Europe & North America. And now we have operations in Malaysia, Sri Lanka, Bangladesh, Indonesia and South Africa. 
In 4th year of our business we will focus on accelerating our growth strategy while continuing to build on the strength of our brand—by sharing the knowledge of our services & strength through effective marketing. However, we will not follow the conventional method of marketing also. It will be as unique as our “Disease Surveillance Report”. We are very excited about this and truly believe that this will bring a trend in our fraternity. This will also be our first step towards expansion with stability, better service, and global presence while still offering all advantages of a small size CRO. We are also very excited for our new office in Copenhagen which we will open in May 2013. However, our focus will remain on “Creating Innovation” in our project management implementation. 

Looking back on the trails of time and development I feel proud to be a part of this exciting journey. This keeps me encouraged and intrigues me to reach further out to you, our partner, client and ambassador. 

Thank you everybody. 

Kind Regards,
Dhirendra V. Singh

Sunday, January 27, 2013

Biosimilar Regulation in India

A biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product is known as Biosimilar.

This could be the single fastest-growing biologics sector in the next five years – albeit from a small base – spurred by the convergence of major dynamics that will see new biosimilars enter the US market, bring additional molecules to Europe, and open up oncology and autoimmune disease areas to biosimilars for the first time ever. Biosimilars also bring clear potential for payers in the emerging pharmaceutical or “pharmerging” markets, such as Brazil, China and India. India have developed new regulatory guidelines for Biosimilar.

In New guideline DCGI has made mandatory the preclinical evaluation of biosimilar. The non-clinical studies should be comparative in nature and design to detect differences if any, between the similar biologics and innovator recombinant product. These should be conducted with the final formulation of the similar biologics intended for clinical use, unless otherwise justified. The non-clinical study design may vary depending upon the clinical parameters such as therapeutic index, the type and number of indications applied for etc. Assays like receptor binding studies or cell based assays (e.g. cell proliferation assays) should be conducted, when appropriate to establish comparability of biological activity. In cases where invitro assays do not reflect the pharamacodynamics, in-vivo studies should be performed. Comparative repeat dose toxicity with immunogenicity testing is also made compulsory in given route of administration, local tolerance should be evaluated.

According to new guideline, comparative Pharmacokinetic (PK) study on healthy subjects, Pharmacodynamics (PD) studies in most patients or healthy volunteers. If PD marker is available in healthy volunteers, PD in healthy volunteers can be done. Followed by a Phase III, Comparative safety and efficacy in relevant patient population is also mandatory for all biosimilar. However, in certain cases it can be waived. DCGI has also mandated the submission of PSUR 6 monthly for first 2 years and then annually for next 2 years, along with a Post Market study.

Regulatory applications and approvals issued at different stages of biosimilars product development

No.
Stage
Agency involved
Application
  Approval
1
Manufacturing permission for test, analysis & examination
DCGI
Not Spesific
Permission (Manufacturing NOC)
2
Manufacturing License for test, analysis & examination
Local FDA
Form 30
Form 29
3
R & D
Institutional Biosafety
Committee (IBSC)
Not Spesific
Permission
(IBSC minutes)
4
Non-Clinical studies permission
RCGM
Form C3
Form C4
5
Submission of Non-clinical study report
RCGM
Form C5
Form C6
6
Clinical Trials
 DCGI
Form 44
Permission
(CT NOC)
7
Manufacturing License for CT batches
Local FDA (subject to CT NOC)
Form 30
Form 29
8
Manufacturing & Marketing permission
DCGI
Form 44
1. Form 45/46 (Finished product)
2. Form 46A (Bulk product)
9
Commercial Manufacturing License
Local FDA
Form 27 D
Form 28 D

Kind Regards,

Sunday, January 13, 2013

Genelife Clinical Research- Ongoing Medical Device Clinical Trials

Genelife Clinical Research has started its first Medical Device Pilot Clinical Study for US FDA submission. Although we have participated in couple of US FDA studies in past but both were Pharmaceutical Clinical Trials. This is first time we are going to start a Medical Device Clinical Trials for Medical Device, within ENT therapeutic area. 

The study will be performed in a single site in India and we are hoping to recruit all patient volunteers in one month. The site selection procedure was dependent on not only the historic performance, type of Institute and its geographic location, paramedical staff, Investigator’s qualifications but we also considered the importance of patient referral. This we did considering the importance of project as well as the dependence of season on recruitment. 

Like our past studies we are hoping to complete this study before the time we proposed to our Sponsor. Hope we will achieve our target.


Kind Regards,